TheraSphere® is a powerful*, well-tolerated liver cancer therapy that consists of millions of small glass microspheres (20 to 30 micrometers in diameter, or about a third of the width of a human hair) containing radioactive yttrium-90. The product is injected by physicians into the artery of the patient’s liver through a catheter, which allows the treatment to be delivered directly to the tumor via blood flow.
This approach provides a high concentration of radiation treatment directed to the tumor, and limits both damage to surrounding healthy tissue and side effects for the patient that often result from other forms of cancer treatment, such as external radiation or systemic therapy. This form of radioembolization therapy also keeps future treatment options open as patients progress through the later stages of their disease.
TheraSphere® is used in the European Union and in Canada for the treatment of hepatic neoplasia in patients who have appropriately positioned arterial catheters.
*Refers to high specific activity.